ADReCS

Pharmaceutical Information

Drug Name	Azacitidine
Drug ID	BADD_D00194
Description	A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage	For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status	approved; investigational
ATC Code	L01BC07
DrugBank ID	DB00928
KEGG ID	D03021
MeSH ID	D001374
PubChem ID	9444
TTD Drug ID	D09FAZ
NDC Product Code	0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII	M801H13NRU
Synonyms	Azacitidine \| 5-Azacytidine \| 5 Azacytidine \| Azacytidine \| Vidaza \| NSC-102816 \| NSC 102816 \| NSC102816

Chemical Information

Molecular Formula	C8H12N4O5
CAS Registry Number	320-67-2
SMILES	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Acute kidney injury	20.01.03.016	0.002630%
Upper-airway cough syndrome	22.12.03.036	-	-
Functional gastrointestinal disorder	07.11.01.016	0.000112%		Not Available
Neuropsychiatric syndrome	17.02.10.014; 19.07.03.009	0.000112%		Not Available
Central nervous system haemorrhage	24.07.04.016; 17.08.01.035	0.000168%		Not Available
Leukostasis syndrome	22.01.03.008; 16.32.03.018; 17.02.10.018; 01.02.01.011	0.000112%		Not Available
Multiple organ dysfunction syndrome	08.01.03.057	0.002183%
Myeloproliferative neoplasm	01.13.03.006; 16.21.03.006	0.000112%		Not Available
Acute myelomonocytic leukaemia	16.01.05.005; 01.10.05.005	0.000112%		Not Available
Aortitis	24.12.01.001	0.000112%		Not Available
Breast cancer recurrent	21.05.01.017; 16.10.01.009	0.000168%		Not Available
Cerebellar haemorrhage	24.07.04.023; 17.08.01.046	0.000112%		Not Available
Chloroma	16.01.08.003; 01.10.08.003	0.000672%		Not Available
Concomitant disease aggravated	08.01.03.063	0.000224%		Not Available
Haemorrhoids thrombosed	24.10.02.006; 07.15.03.005	0.000112%		Not Available
Lung adenocarcinoma	22.08.01.007; 16.19.01.002	0.000224%		Not Available
Pancreatic carcinoma metastatic	16.13.10.003; 07.21.09.006	0.000112%		Not Available
Recurrent cancer	16.16.01.015	0.000112%		Not Available
Splenic haemorrhage	12.01.17.020; 24.07.01.080; 01.09.02.015	0.000112%		Not Available
Systemic mastocytosis	16.21.01.008; 01.13.01.008; 10.02.01.014	0.000112%		Not Available
Urinary bladder haemorrhage	24.07.01.086; 20.03.01.023	0.000168%		Not Available
Anaemia of malignant disease	01.03.04.003	0.000112%		Not Available
Blast crisis in myelogenous leukaemia	16.01.08.002; 01.10.08.002	0.000112%		Not Available
Tumour associated fever	16.32.03.029	0.000112%		Not Available
Small intestinal haemorrhage	24.07.02.019; 07.12.03.002	0.000112%
Bone marrow necrosis	24.04.09.002; 01.05.01.012	0.000168%		Not Available
Acute myeloid leukaemia recurrent	16.01.05.004; 01.10.05.004	0.003694%		Not Available
Leukaemia recurrent	16.01.03.005; 01.10.03.005	0.000672%		Not Available
Graft versus host disease in skin	23.07.04.025; 12.02.09.031; 10.02.01.062	0.000504%		Not Available
Graft versus host disease in liver	12.02.09.029; 10.02.01.060; 09.01.07.033	0.000336%		Not Available

The 17th Page First Pre 17 18 19 Next Last Total 19 Pages